Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Current Problems in Cancer
- Vol. 43 (3) , 222-227
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Correlates of resistance and relapse during blinatumomab therapy for relapsed/refractory acute lymphoblastic leukemiaAmerican Journal of Hematology, 2017
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane traffickingBlood, 2017
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationBlood, 2012
- Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 casesLeukemia & Lymphoma, 2011
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- Bone marrow vs extramedullary relapse of acute leukemia after allogeneic hematopoietic cell transplantation: risk factors and clinical courseBone Marrow Transplantation, 2003
- Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody constructLeukemia, 2003
- Intensified and Shortened Cyclical Chemotherapy for Adult Acute Lymphoblastic LeukemiaJournal of Clinical Oncology, 2002